Endo Pharmaceuticals Holdings Inc.'s reported its more than doubled fourth-quarter earnings, surpassing analysts' speculations, amid a $60 million accounting gain as the company posted that it witnessed a double-digit sales growth of both its branded and generic drugs.

Endo fourth-quarter profit registered to be $147.8 million, or $1.25 a share, up from $72.7 million, or 62 cents, the previous year. Excluding items such as the accounting gain, earnings reported a jump to 81 cents from 74 cents while revenue widened 13% to $391.4 million.

Excluding one-time items, the company earned 81 cents a share in the quarter.

The company estimates to fetch a profit of $3.15 to $3.20 per share, excluding items in 2010, on revenue of $1.55 billion to $1.60 billion, on varied growth in its core operations. However, analysts were predicting a profit of $2.87, before special items, on revenue of $1.53 billion, for the period.

In addition, it posted its revenue to increase by 13 percent to $391.4 million. Analysts, on average, speculated a 68 cents gain, before special items, on revenue of $378.5 million, according to Thomson Reuters I/B/E/S.

Sales of the company's pain drug Opana grew 22 percent, while generic sales rose 21 percent.